## What Would be Required to

## **Prove Non-Target Effects**

## of Vaccination ?

Stanley A. Plotkin

## What is being claimed by Aaby et al. ?

BCG vaccination reduces later mortality due to other disease.

Early measles vaccination reduces later mortality due to other diseases.

DTP vaccination increases later mortality and neutralizes the positive effects of BCG and measles vaccinations.

High titer measles vaccine increases mortality in girls, possibly due to concomitant DTP.

These effects are most influenced by last the vaccine received.

**Observational Studies** DTP 1 mortality BCG 🚽 mortality Measles vaccine - Mortality (Guinea-Bissau, Denmark) Pentavalent vaccine  $\uparrow$  mortality OPV **I** response to IPV **Controlled Trials** Measles vaccine  $\Downarrow$  mortality in absence of Vit A or IPV BCG **U** mortality in prematures BPV U beneficial effect of BCG BCG **1** cytokine production OPV - beneficial effect of BCG

## **Confirmatory Studies Outside Guinea Bissau**

**Prospective cohort in Uganda: BCG reduced mortality by 53%, 26% in 1-5 year olds** 

Measles-Yellow fever vaccine, but not DTP-Hib-Hep vaccine, reduced nasopharyngeal carriage of H. influenza and pneumococci **Possible Mechanisms for Vaccine Effects on Mortality** 


Positive effect:Th1 responseTh17 responseMemory CD4 cellsCytokine response (IL17, IL22, IL 1β IL-6,<br/>TNFαl, IFN%NK cell memoryEpigenetic programming of monocytes and NK cells

Negative effect: Th2 response CMV seropositivity

#### **Possible prophylactic effectiveness of enterovirus infection** (LEV) and OPV in influenza and acute diseases

Group	Vaccinat OPV	ed with Ll	EV or	Internal control (no LEV)			Reduction of influenza incidence	
	total	developed disease		total	developed disease			
		n	%		n	%	ratio	%
I	11,799	418	3.55	8,218	486	5.91	1.7	41.2
II	40,678	6,305	15.50	18,880	5,456	28.90	1.9	46.4
Ш	99,575	5,634	5.71	40,419	7,163	17.71	3.1	67.7
Total	152,042	12,407	8.16	67,517	13,105	19.41	2.4	57.4

#### **BCG vaccination confers partial protection against P. yoelii 17XNL infections in mice.**



Parra M, Liu X, Derrick SC, Yang A, Tian J, et al. (2013) Molecular Analysis of Non-Specific Protection against Murine Malaria Induced by BCG Vaccination. PLoS ONE 8(7): e66115. doi:10.1371/journal.pone.0066115

## Protection of mice against Babesia and Plasmodium with BCG

Division of Cell Pathology Clinical Research Center Watford Road Harrow, UK I.A. Clark A.C. Allison

Department of Zoology University of London Strand, London WC2, UK *F.E. Cox* 

# **Comparison of GMC of IgG for each vaccine between BCG-immunised and non-BCG-immunised groups.**

Vaccine	Geometric mear (GMC) of IgG	p-value		
	BCG-immunised (n = 56)	Non-BCG-immunised (n = 52)		
Pneumococcus				
Serotype 4	3.50	3.33	0.71	
Serotype 6B	5.06	3.47	0.06	
Serotype 9V	3.86	2.62	< 0.01	
Serotype 11A <sup>a</sup>	0.06	0.06	0.50	
Serotype 14	9.77	8.69	0.43	
Serotype 18C	3.09	2.32	0.04	
Serotype 19F	3.69	3.14	0.18	
Serotype 23F	3.80	3.32	0.50	
Haemophilus influenzae type b	4.05	3.17	0.37	
Tetanus	2.88	2.49	0.19	
Hepatitis B	2908	4161	0.03	

Ritz et al, Vaccine, 2013 June 26:31(30): 3098–3103

# **Sex-stratified effect of BCG strain on cytokine responses to tetanus toxoid (TT) and BCG scar frequency in Uganda**

Cytokine Sex (M/F)		Russia ( <i>n</i> = 719)	Bulgaria ( <i>n</i> = 508)	Denmark ( <i>n</i> = 114)	
		Geometric mean (pcg/ml)	Geometric mean (pcg/ml)	Geometric mean (pcg/ml)	
IFN-γ	M	34.2	1.04	59.2	
	F	23.9	25.23	115.3	
ПБ	M	12.3	11.63	13.6	
IL-5	F	10.0	6.94	19.7	
IL-13	M	46.1	38.29	35.1	
1L-13	F	40.4	26.28	74.9	
IL-10	M	4.1	9.59	6.7	
1L-10	F	2.7	7.70	15.9	
BCG scar frequency (%)					
	M	182 (51.9%)	173 (65.3%)	53 (93.0%)	
	F	170 (46.3%)	160 (65.8%)	53 (93.0%)	

Anderson E., Vaccine, 2012 March 9:30(12): 2083–2089

## The NK Cell

Third lineage of lymphocytes

Important response to CMV infection, persisting for years.NK cells increase after multiple infections.e.g. vaccinia, influenza, hanta, particularly CMV

NK memory long-lived, depends on IL-15.

Transferred NK cells are active and protective.

Lactobacillus administration stimulates NK

Sun et al. EMBO J ., 2014 Foley et al, J. Immunol, 2012 Kawashira et al, Vaccine 2014

### **Other Non-Specific Activities**

- Gamma-Delta T cells in the intestine
- Th1 + Th2 responses induced by BCG
   ↑ responses to OPV and Hepatitis B vaccines
- BCG increased CD4+ T cell responses to vaccinia
- Th2 response by acellular pertussis vaccines
- Candida programs monocytes against reinfection in the absence of B or T cells.

Sun et al, EMBO J, 2014 Ota et al, J immunol, 2002 Quintm et al, Cell 2012 Mathurin et al, J Virol, 2009 **Another Factor to Consider ?** 

**The Microbiome** 

TLR-5 Stimulation by flagellin on flagella influences responses to influenza vaccine

Gut overgrowth decreases response to oral cholera vaccine

Antibiotic treatment but also lactobacilli increases IgA response to rotavirus vaccine

**Enteric bacteria enhance growth of norovirus** 

**OPV** immunogenicity decreased in malnourished infants

Oh, et al. Immunity 2014, Lages et al, JID, 1999, Uchiyama et al, JID 2014 Jones et al, Science 2014, Kandasany, Gut Microbes, 2014 Saleem et al, Vaccine 2015

#### Vaccines Affect Nasopharyngeal Carriage of Bacteria in Infants

	% Prevalence Before Vaccination	After vaccination
DTP-HibHepB		
pneumo	86.6	89.8
Hib	33.3	33.5
Staph	28.4	21.1
Measles - YF		
Pneumo	93.8	89.0
Hib	41.1	24.8
Staph	18.9	16.4


#### Interactions of Cytomegalovirus With the Immune System

Induction of neutralizing , and ADCC antibodies Induction of CD4+ T cell + CD8+ T cell responses to the virus

#### Also CMV


Produces proteins that downgrade antiviral T cell responses
Produces proteins that downgrade NK cell responses to first infection but increase NK memory
Produces gamma-delta T cells that increase antibody responses to donor grafts
Produces Treg cells that decrease inflammation
T cell responses to CMV may decrease responses to other antigens
Increases risk of coronary and cerebrovascular events in HIV infected (inflammation)

Terrazzini + Kern, F1000 Prime Reports 2014, Lichtner, JID, 2015 Couzi et al, Front Immunol, 2015 Boeckh et al, Biol Blood Marrow Transpl. 2015 Lee, Immunity, 2015 Geometric mean ratio (GMR) of in vitro cytokine production, comparing BCG-vaccinated to nonvaccinated overall and stratified by sex.




Kristoffer Jarlov Jensen et al. J Infect Dis. 2015;211:956-967

# **BCG enhances NK cell production of proinflammatory cytokines**



Kleinnijenhuis, Clinical Immunology, 2014 December 155(2): 213-219

## **BCG Increases Th1 and Th17 Responses Against Heterologous Antigens**



## Randomized Trial in Guinea Bissau BCG vs BCG + OPV at birth

# Combined vaccination J IFN and IL-5 Reponses to PPD at 2-6 weeks

#### Need to Look Also at Children in Developed Countries

- Mortality is easy to measure but insignificant in those countries
- Hospitalization and medical visits are better endpoint
- Immune markers should be influenced and measurable
- However, a study in Holland showed no effects on gender mortality after DTP-IPV vs. MMR


## **Measles and Immune Suppression**

 Measles virus replicates in dendritic cells, memory cells, memory T cells (CD150+) and follicular B cells


Lymphopenia is transitory

 However, new lymphocytes are directed against measles and memory against other antigens is lost

## Immune Memory Loss as Conceived by Mina et al, Science 2015



#### **Decrease in Mortality Parallels Decrease in Measles**



- Until recently, claims for non-specific effects have been made based mainly on observations of mortality.
- However, epidemiology is mostly observational and sometimes conflicting (e.g. New Guinea vs. Guinea-Bissau)
- Only randomized epidemiology is convincing
- Proof must be buttressed by an immunological explanation.
- Mortality is a gross end point. Causes must be defined.

## What Should be Studied?

- Antibodies, particularly functionality
- > Th cell orientation: 1, 2, 17
- Cytokine production and other innate immune responses
- NK activation
- > CD8 T cells, effector and memory
- Coinfection with herpesvirus

#### Bacillus Calmette-Guérin immunisation at birth and morbidity among Danish children: A prospective, randomised, clinical trial.

Lisbeth Marianne Thøstesen, Thomas Nørrelykke Nissen, Jesper Kjærgaard, Gitte Thybo Pihl, Nina Marie Birk, Christine Stabell Bennd, GormGreisen, Poul-Erik Kofoeda, Ole Pryds, Henrik Ravn, Dorthe Lisbeth Jeppesen, Peter Aaby , Lone Graff Stensballe

**Methods:** The Danish Calmette Study is amulticentre randomised clinical trial conducted between October 2012 and November 2015. Within the first 7 days of life, infants were randomly assigned to intra-dermal vaccination with BCG or no intervention. At 3 and 13 months of age structured telephone interviews and clinical examinations of the children were conducted. In a subgroup of children blood samples were drawn and stool samples collected at age 4 days, 3 and 13 months. Thymus index was assessed by ultrasound in a subgroup at randomisation and at 3 months. The primary study outcome is hospitalisation within the first 15 months of life as assessed in Danish health registers. Secondary outcomes include infectious disease hospitalisations, wheezing, eczema, use of prescribed medication, growth, development, thymus index, T- and B-cell subpopulations assessed by flow cytometry, in vitro cytokine responses and specific antibody responses to other vaccines. Adverse reactions were registered.

## **In Summary**

Non-specific effects exist and are a valid field of study.

Emphasis must now be put on immunological mechanisms.

Demonstration of similar effects in developed countries, even without mortality, would help validate findings in developing countries. However, more controlled studies are needed in developing countries.

The work of Aaby et al has been justified, although much needs to be clarified.

There is nothing more difficult to take in hand, more perilous to conduct, or more uncertain in its success, than to take the lead in the introduction of a new order of things. Niccolo Machiavelli